North China Pharmaceutical H1 Net Profit Falls 48.3% to RMB 63.85 Million
North China Pharmaceutical reported first-half 2026 results on August 21, with revenue of RMB 4.22 billion, down 20.01% year on year. Net profit attributable to shareholders fell 48.3% to RMB 63.85 million, while basic earnings per share stood at RMB 0.037. The declines reflect weaker operating performance in the period.
North China Pharmaceutical disclosed its semi-annual report on August 21, 2026. In the first half of 2026, the company posted operating revenue of RMB 4.22 billion, a year-on-year decrease of 20.01%. Net profit attributable to shareholders of the listed company was RMB 63.85 million, down 48.3% from the same period last year. Basic earnings per share amounted to RMB 0.037.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is negative for Pharmaceuticals, with intensity 40/100 and 70% confidence over a short term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.